Moderna (MRNA) Down 92% from All-Time High – What's Next?
Overview:
Moderna (MRNA) has fallen sharply, trading 92% below its all-time high of $497.49 (reached in 2021). With this massive decline, investors might wonder: Is the stock poised for a recovery or headed lower?
Key Insights:
Support Levels:
Current price hovers near the 2020 pre-pandemic breakout zone (~$30-$40), a strong historical support area.
Catalysts to Watch:
Pipeline Updates: Moderna's future depends heavily on non-COVID vaccine developments. Any positive trial data could spark a rally. Broader Market Trends: If biotech stocks gain traction, MRNA could benefit as a high-beta play.
Moderna (MRNA) has fallen sharply, trading 92% below its all-time high of $497.49 (reached in 2021). With this massive decline, investors might wonder: Is the stock poised for a recovery or headed lower?
Key Insights:
Support Levels:
Current price hovers near the 2020 pre-pandemic breakout zone (~$30-$40), a strong historical support area.
Catalysts to Watch:
Pipeline Updates: Moderna's future depends heavily on non-COVID vaccine developments. Any positive trial data could spark a rally. Broader Market Trends: If biotech stocks gain traction, MRNA could benefit as a high-beta play.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。